Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

Heinz Ludwig; Thomas Melchardt; Siegfried Sormann; Martin Schreder; Johannes Andel; Bernd Hartmann; Christoph Tinchon; Niklas Zojer; Eberhard Gunsilius; Klaus Podar; Alexander Egle; Wolfgang Willenbacher; Ewald Wöll; Reinhard Ruckser; Boris Bozic; Maria-Theresa Krauth; Andreas Petzer; Clemens Schmitt; Sigrid Machherndl-Spandl; Hermine Agis; Michael Fillitz; Song-Yau Wang; August Zabernigg; Stefan Knop; Bruno Paiva; Richard Greil

doi:10.1002/ajh.27280

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29.

Authors

Heinz Ludwig¹, Thomas Melchardt², Siegfried Sormann³, Martin Schreder⁴, Johannes Andel⁵, Bernd Hartmann⁶, Christoph Tinchon⁷, Niklas Zojer⁴, Eberhard Gunsilius⁸, Klaus Podar^{9

10}, Alexander Egle², Wolfgang Willenbacher^{8

11}, Ewald Wöll¹², Reinhard Ruckser¹³, Boris Bozic¹³, Maria-Theresa Krauth¹⁴, Andreas Petzer¹⁵, Clemens Schmitt¹⁶, Sigrid Machherndl-Spandl¹⁷, Hermine Agis¹⁸, Michael Fillitz¹⁹, Song-Yau Wang²⁰, August Zabernigg²¹, Stefan Knop²², Bruno Paiva²³, Richard Greil²

Affiliations

¹ Department of Medicine I, Clinic Ottakring, Wilhelminen Cancer Research Institute, Vienna, Austria.
² Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
³ Department of Hematology, University Clinic for Internal Medicine, Graz, Austria.
⁴ Department of Medicine I, Clinic Ottakring, Vienna, Austria.
⁵ Department of Internal Medicine II, Pyhrn-Eisenwurzen Klinikum Steyr, Steyr, Austria.
⁶ Department of Internal Medicine II, LKH Rankweil, Rankweil, Austria.
⁷ Department for Hematology, Oncology and Palliative Care, LKH Hochsteiermark, Standort Leoben, Standort Leoben, Austria.
⁸ Department of Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria.
⁹ Department of Internal Medicine II, University Hospital Krems, Krems an der Donau, Austria.
¹⁰ Molecular Oncology and Hematology Unit, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.
¹¹ syndena GmbH, Connect to Cure, Innsbruck, Austria.
¹² Department of Internal Medicine, St. Vinzenz Krankenhaus Zams, Zams, Austria.
¹³ Department of Medicine II, Clinic Donaustadt, Vienna, Austria.
¹⁴ University Clinic for Internal Medicine I, AKH, Medical University of Vienna, Vienna, Austria.
¹⁵ Department of Internal Medicine I, BHS Linz, Linz, Austria.
¹⁶ Clinic for Internal Medicine 3, Kepler University Clinic Linz, Linz, Austria.
¹⁷ Department of Internal Medicine I, Elisabethinen, Linz, Austria.
¹⁸ Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria.
¹⁹ Department of Internal Medicine, Hanusch Krankenhaus, Vienna, Austria.
²⁰ Medical Clinic and Policlinic I, University Clinic Leipzig, Leipzig, Germany.
²¹ Department of Internal Medicine, Kufstein County Hospital, Kufstein, Austria.
²² Klinik für Innere Medizin 5, Schwerpunkt Onkologie/Hämatologie, Klinikum Nürnberg Nord, Nürnberg, Germany.
²³ Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), CCUN, IDISNA, Pamplona, Spain.

PMID: 38425185
DOI: 10.1002/ajh.27280

Abstract

Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Dexamethasone / therapeutic use
Humans
Induction Chemotherapy
Lenalidomide / therapeutic use
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy

Substances

Dexamethasone
Lenalidomide

Abstract

Publication types

MeSH terms

Substances

Grants and funding